Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction

Journal of Gene Medicine

Volumn 12, Issue 3, 2010, Pages 255-265

  Liang, Min ^a   Kamata, Masakazu ^a   Chen, Kevin N ^a   Pariente, Nonia ^a   An, Dong Sung ^a   Chen, Irvin S Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CCRS; Hematopoietic progenitor cells; HIV 1; Lentiviral vector; Macrophages; shRNA

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; STEM CELL FACTOR;

ARTICLE; CD34 SELECTION; CELL DIFFERENTIATION; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA INTERFERENCE; VIRUS CELL INTERACTION;

CELL LINE; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; RECEPTORS, CCR5; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77349124962     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1440     Document Type: Article

References (45)

1. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous versus sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998; 280: 35-41.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl J Med 1997; 337: 734-739.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New Engl J Med 1997; 337: 725-733.
4. Brau N, Leaf HL, Wieczorek RL, et al. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997; 349: 924-925.
5. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499-507.
6. NunezM, LanaR, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426-431.
7. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
8. Li MJ, Bauer G, Michienzi A, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206.
9. Qin XF, An DS, Chen IS, et al. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188.
10. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-686.
11. Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
12. Anderson J, Akkina R. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther 2007; 14: 1287-1297.
13. Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601-2605.
14. Westerhout EM, ter Brake O, Berkhout B. The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology 2006; 3: 57.
15. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-1148.
16. Rana S, Besson G, Cook DG, et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J Virol 1997; 71: 3219-3227.
17. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.
18. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
19. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377.
20. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
21. Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-1010.
22. Banerjea A, Li MJ, Bauer G, et al. Inhibition ofHIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther 2003; 8: 62-71.
23. Fish RJ, Kruithof EK. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Molecular Biol 2004; 5: 9.
24. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
25. Jackson AL, Burchard J, Schelter J, et al.Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12: 1179-1187.
26. Snove O, Jr., Rossi JJ. Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol 2006; 7: 231.
27. An DS, Qin FX, Auyeung VC, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006; 14: 494-504.
28. An DS, Donahue RE, Kamata M, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007; 104: 13110-13115.
29. Shimizu S, Kamata M, Kittipongdaja P, et al. Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet Vaccines Ther 2009; 7: 8.
30. Zaitseva M, Blauvelt A, Lee S, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 1997; 3: 1369-1375.
31. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997; 185: 1681-1691.
32. Bennett S, Breit SN. Variables in the isolation and culture of human monocytes that are of particular relevance to studies of HIV. J Leukoc Biol 1994; 56: 236-240.
33. Akkina RK, Rosenblatt JD, Campbell AG, et al. Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood 1994; 84: 1393-1398.
34. Kamata M, Nagaoka Y, Chen IS. Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog 2009; 5: e1000342.
35. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.
36. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
37. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-489.
38. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New Engl J Med 2009; 360: 692-698.
39. DoranzBJ, Rucker J, YiY, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-1158.
40. Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87: 745-756.
41. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
42. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007; 4: 11.
43. Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 2006; 303: 97-120.
44. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005; 13: 269-277.
45. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 2007; 58: 445-459.